Actualización en síndrome hemolítico urémico atípico: diagnóstico y tratamiento. Documento de consenso

Overview of attention for article published in Nefrología, October 2015

Altmetric Badge

Mentioned by

policy: 1 policy source

twitter: 2 X users

Citations

dimensions_citation: 155 Dimensions

Readers on

mendeley: 232 Mendeley

Summary Policy documents X Dimensions citations

So far, Altmetric has seen 2 policy documents that reference this research output.

ravulizumab

Cited by Canadian Agency for Drugs and Technologies in Health on 07 Jun 2023

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

Management of Atypical Hemolytic Uremic Syndrome: Clinical Effectiveness and Guidelines

Cited by Canadian Agency for Drugs and Technologies in Health on 30 May 2018

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.